|
KMID : 0358420080510070738
|
|
Korean Journal of Obstetrics and Gynecology
2008 Volume.51 No. 7 p.738 ~ p.743
|
|
|
The correlation of clusterin binding affinity to chemotherapeutic agents with chemoresistance in ovarian cancer cells
|
|
Choi Joo-Hyuk
Suh Min-Jung
Park Dong-Choon
|
|
|
Abstract
|
|
|
Objective: The purpose of this study was to determine the mechanism of action of clusterin?known as a chemo-resistance protein?by analyzing its binding with chemotherapeutic agents and elucidating its relation with drug resistance.
Methods: Chemotherapeutic agents were diluted with coating buffer and coated onto 96 well plates. We then had these agents cross-react with purified clusterin and wash the wells to remove residual clusterin. We quantified the amount of clusterin with optical density (OD) measured by binding peroxidase-conjugated secondary antibody associated with mouse monoclonal clusterin antibody. To determine if anticancer drug-clusterin binding is related to chemotherapeutic agent resistance, we compared survival rates in the SKOV-3 cell line, which rarely secretes clusterin. We compared a group of SKOV-3 cells treated with a chemotherapeutic agent and a group treated with both the agent and clusterin, by means of XTT.
Results: In binding tests using ELISA OD, ratios of paclitaxel, cisplatin, carboplatin, topotecan, Adriamycin, etoposide, and 5-fluoruracil (5-FU) were 2.34, 2.40, 0.52, 2.44, 1.602, 1.14, and 1.13, respectively. Topotecan, cisplatin, and paclitaxel showed relatively higher binding. In addition, when these drugs were treated with clusterin in SKOV-3 cells, anticancer resistance increased (P<0.05).
Conclusions: The anticancer drug resistance endowed by clusterin is considered to be related to its binding with chemotherapeutic agents.
|
|
|
KEYWORD
|
|
|
Clusterin, Drug binding, Chemo-resistance, Ovarian cancer
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|
|